The historical rank and industry rank for Biotechnology Assets's Days Payable or its related term are showing as below:
During the past 13 years, Biotechnology Assets's highest Days Payable was 2573.62. The lowest was 221.82. And the median was 729.53.
XMAD:BST's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
Biotechnology Assets's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Biotechnology Assets Days Payable Related Terms
Biotechnology Assets Days Payable Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Biotechnology Assets's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Days Payable distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biotechnology Assets's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets (XMAD:BST) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biotechnology Assets and its competitors. Over the past decade, Biotechnology Assets' Days Payable has ranged from 221.82 to 2,573.62. According to the industry distribution chart, Biotechnology Assets ranks #999999 out of 707 companies in the Biotechnology industry.
Is Biotechnology Assets' Days Payable too high?
Biotechnology Assets' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 221.82 to a high of 2,573.62. Based on the distribution chart, Biotechnology Assets ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biotechnology Assets has a GF Score™ of 19/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #999999 out of 707 companies for Days Payable. This places Biotechnology Assets in the lower half of its industry. The industry median Days Payable is 113.76. Historically, Biotechnology Assets' own Days Payable has ranged from 221.82 to 2,573.62 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biotechnology Assets and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotechnology Assets's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.23 — trading 24.7% below its estimated fair value. The current Days Payable is 0.00. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.23 is trading 24.7% below its estimated GF Value™ of €0.30.
GuruFocus considers Biotechnology Assets to be Modestly Undervalued.
Key valuation signals for XMAD:BST:
Days Payable: 0.00
GF Value™: €0.30 vs. price of €0.23 (24.7% below fair value)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score
Get the complete analysis for XMAD:BST
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
